Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EMERALD TRIAL Open-Label Extension Study (EMERALD OLE)

NCT04997954 is registered in ClinicalTrials.gov with Gold Coast Hospital and Health Service as lead sponsor.

NCT NCT04997954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04997954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EMERALD TRIAL Open-Label Extension Study (EMERALD OLE)
Lead sponsor
Gold Coast Hospital and Health Service
Phase
Phase 4
Overall status
Unknown status
Start date
May 17, 2021
Completion date
January 31, 2024
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis, cannabis, cbd, motor neuron disease